Target intelligence / Profile preview

RNA, U6 small nuclear 610, pseudogene (RNU6-610P)

Target
RNU6-610P
Molecular classification
Pseudogene, Non-coding RNA (derived from small nuclear RNA snRNA family), Other
01

Overview

RNU6-610P is a human pseudogene derived from the U6 small nuclear RNA gene. U6 snRNA is normally a critical component of the spliceosome, which catalyzes the removal of introns from pre-mRNA during splicing[1][3]. However, RNU6-610P represents a defective, non-functional copy of the U6 snRNA gene lacking protein-coding ability, and by definition does not participate in the canonical functions associated with U6 snRNA. Pseudogenes like RNU6-610P can be transcribed and may, in rare cases, exert regulatory functions by acting as decoys for miRNAs or participating in chromatin remodeling, but no disease role, therapeutic value, or drug interaction is established for this specific pseudogene[2][4][5]. The "610" in its name specifies its locus or variant number in the human genome. Key insight: RNU6-610P is not a drug target; it is a transcriptionally inactive locus classified as a pseudogene. Its presence and potential regulatory effects are the subject of genomic and transcriptomic research, but it holds no current direct relevance for pharmacology, therapy, or biomarker development[2][4][5].

Other names
RNU6-610PU6-610 pseudogeneU6 small nuclear RNA pseudogene 610
02

Mechanism of action

None directly applicable (as above)

03

Biological functions

May serve as a competing endogenous RNA (ceRNA), potentially modulating the expression of related genes via miRNA spongingPossible involvement in chromatin remodeling and epigenetic regulationNo canonical or essential cellular functions known; not directly involved in splicing due to loss of function
04

Disease associations

Other (some pseudogenes are implicated in regulatory functions but there is no specific evidence associating RNU6-610P with any disease state)Occasionally pseudogenes can act as decoys or regulators impacting parental gene activity, but the disease relevance of RNU6-610P is not established
05

Safety considerations

None (As it is non-functional, there are no known therapeutic safety issues or development challenges)
06

Interacting drugs

None (There are no known pharmacological agents targeting RNU6-610P as it is not an active biological molecule)
07

Biomarkers

None (No established use of RNU6-610P as a biomarker for patient selection or monitoring)

Beyond the preview

Go deeper on RNA, U6 small nuclear 610, pseudogene (RNU6-610P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 610, pseudogene (RNU6-610P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call